Published in J Virol on June 10, 2016
Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV) | NCT02227277
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proc Natl Acad Sci U S A (2017) 0.84
Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest (2016) 0.78
Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathog Immun (2016) 0.77
ADAR1 and PACT contribute to efficient translation of transcripts containing HIV-1 trans-activating response (TAR) element. Biochem J (2017) 0.75
Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice. Oncotarget (2016) 0.75
Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells. Retrovirology (2016) 0.75
Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference. Front Immunol (2017) 0.75
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med (1998) 4.52
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol (2005) 3.89
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature (2013) 2.79
Intrinsic antiviral immunity. Nat Immunol (2012) 2.71
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 2.39
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol (2013) 2.22
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature (2014) 2.20
Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A (2009) 1.99
Control of human viral infections by natural killer cells. Annu Rev Immunol (2013) 1.96
The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem (2007) 1.91
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med (2005) 1.68
Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol (2006) 1.67
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc (2008) 1.60
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55
DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol (2003) 1.54
Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol (2002) 1.53
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 1.51
Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol (1995) 1.48
Characterization of the type I interferon locus and identification of novel genes. Genomics (2004) 1.36
Evolutionary genetic dissection of human interferons. J Exp Med (2011) 1.32
Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol (2005) 1.28
Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol (2012) 1.28
Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A (2000) 1.26
Binding and activity of all human alpha interferon subtypes. Cytokine (2011) 1.24
An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem (2007) 1.21
Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One (2013) 1.19
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol (2014) 1.19
Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes. J Immunol (2005) 1.16
HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol (2015) 1.14
A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Res Hum Retroviruses (2000) 1.10
Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Blood (2012) 1.07
Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog (2013) 1.04
Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines. AIDS Res Hum Retroviruses (2010) 1.02
Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe (2015) 1.01
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res (2010) 0.99
Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection. PLoS Pathog (2014) 0.98
Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis (2013) 0.98
Preferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res Hum Retroviruses (2009) 0.98
Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood (2002) 0.98
HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol (2012) 0.98
Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog (2012) 0.97
Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection. Proc Natl Acad Sci U S A (2014) 0.97
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis (1997) 0.95
Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. Retrovirology (2014) 0.93
Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res (2008) 0.91
A structural basis for interferon-alpha-receptor interactions. FASEB J (2007) 0.91
TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am J Pathol (2011) 0.91
IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol (2013) 0.90
Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol (2009) 0.90
Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J Immunol (2014) 0.90
Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin Transl Immunology (2014) 0.89
Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol (2013) 0.89
Structural variants of IFNα preferentially promote antiviral functions. Blood (2011) 0.88
Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog (2015) 0.87
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther (2012) 0.87
Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol Proced Online (2006) 0.85
Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.84
Characterization of murine interferon-alpha 12 (MuIFN-alpha12): biological activities and gene expression. Cytokine (2007) 0.83
Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)γc(-/-)CD47(-/-) background. J Immunol Methods (2014) 0.81
The in vivo expression patterns of individual type I interferon genes in murine cytomegalovirus infections. Antiviral Res (1997) 0.80
Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology (2014) 0.80
Characterization of murine IL-1 beta. Isolation, expression, and purification. J Immunol (1988) 0.77
Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res (2006) 0.77
Plasma interferon-gamma-inducible protein 10 can be used to predict viral load in HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 0.77
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. J Infect Dis (2015) 0.77
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. J Infect Dis (2014) 0.76
PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog (2015) 1.49
Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog (2014) 1.00
Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog (2015) 0.87
Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice. MBio (2015) 0.79
STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat Struct Mol Biol (2017) 0.76
Binding of interferon reduces the force of unfolding for interferon receptor 1. PLoS One (2017) 0.75
Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. Emerg Microbes Infect (2022) 0.75
B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection. MBio (2017) 0.75